· CARTISTEM® paper published in SCI-level sports medicine journal for the first time in Korea
· CARTISTEM® receives international recognition with 5-year follow-up results, boosts prospect for entering global markets
MEDIPOST announced on the 18th that the 48-week and 5-year long-term efficacy follow-up paper on phase 3 clinical trial patients of CARTISTEM®, treatment for knee osteoarthritis, was selected as the best original research of 2021 by the OJSM (Orthopaedic Journal of Sports Medicine).
The OJSM is the SCI-level journal of the AOSSM (American Orthopaedic Society for Sports Medicine) that celebrated its 50th anniversary in 2022. This award screened all journals registered in the OJSM last year and selected 18 journals in three areas. The long-term follow-up journal about CARTISTEM® was selected as the best original research, marking a first for a Korean company.
This journal covers the 48-week and 5-year long-term follow-up results of 89 patients who participated in phase 3 clinical trial. The 5-year long-term result proved that there was a significant improvement in symptoms of knee pain, stiffness, and physical function (WOMAC), subjective pain relief (100mm VAS), and objective knee function (IKDC) and long-term cartilage regeneration. In particular, a significant result was shown in patients with severe symptoms and patients 60 years old or older with large cartilage defects.
Outstanding orthopedic professors from 10 prominent university hospitals in Korea participated in this paper. Dr. Brian J. Cole, a celebrated professor in the global sports medicine world, participated in the review and analysis of this paper as a co-author, which enhanced the value of the journal internationally. Professor Brian J. Cole, also known as the team doctor of the NBA team Chicago Bulls, reconfirmed the safety and efficacy of CARTISTEM® through the U.S. 1/2a phase clinical trials. The U.S. clinical result was published in the JCJP (Journal of Cartilage & Joint Preservation), an SCI-level journal of the ICRS (International Cartilage Regeneration & Joint Preservation Society), in March.
The official of MEDIPOST said “This means CARTISTEM® is globally recognized as a definite treatment option for osteoarthritis patients with severe symptoms and aged patients by improving the knee function and pain in the long-term through cartilage regeneration. Based on this reference, MEDIPOST will accelerate overseas clinical trials to make CARTISTEM® a global blockbuster.”
MEDIPOST acquired OmniaBio, a Canadian company specializing in cell and gene therapy CDMO, in May to advance the CDMO project to North America. MEDIPOST further plans to accelerate the global market entry through the U.S. CARTISTEM® phase 3 and SMUP-IA-01 phase 2 by using North America as a base for clinical and commercialized products of MEDIPOST.
AOSSM (American Orthopaedic Society for Sports Medicine) : The American Orthopaedic Society for Sports Medicine covers the prevention and treatment, rehabilitation, and physical therapy of sports injuries. Established in 1972, it marked its 50th anniversary this year and currently has more than 2,000 members.
OJSM (Orthopaedic Journal of Sports Medicine) : A SCI-level American sports medicine journal began in 2013. It is the official journal of the AOSSM.
ICRS (International Cartilage Regeneration & Joint Preservation Society) : The International Cartilage Regeneration & Joint Preservation Society is an international symposium of regeneration medicine where global experts in cartilage regeneration medicine gather and share research results.
JCJP (Journal of Cartilage & Joint Preservation) : A SCI-level medical journal of ICRS related to cartilage and joint preservation.